JP2016539096A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539096A5 JP2016539096A5 JP2016524116A JP2016524116A JP2016539096A5 JP 2016539096 A5 JP2016539096 A5 JP 2016539096A5 JP 2016524116 A JP2016524116 A JP 2016524116A JP 2016524116 A JP2016524116 A JP 2016524116A JP 2016539096 A5 JP2016539096 A5 JP 2016539096A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- vegf
- composition according
- ctla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 63
- 108090001123 antibodies Proteins 0.000 claims 38
- 102000004965 antibodies Human genes 0.000 claims 38
- 230000003042 antagnostic Effects 0.000 claims 26
- 239000005557 antagonist Substances 0.000 claims 26
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 22
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 22
- WNMJYKCGWZFFKR-UHFFFAOYSA-N Alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 claims 20
- 101710030892 FLT1 Proteins 0.000 claims 12
- 102100006565 FLT1 Human genes 0.000 claims 12
- 102100013180 KDR Human genes 0.000 claims 12
- 101710030888 KDR Proteins 0.000 claims 12
- 150000001413 amino acids Chemical class 0.000 claims 12
- 239000002552 dosage form Substances 0.000 claims 12
- 102000018358 Immunoglobulins Human genes 0.000 claims 4
- 108060003951 Immunoglobulins Proteins 0.000 claims 4
- 108010089187 Ipilimumab Proteins 0.000 claims 4
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 4
- 229950007217 Tremelimumab Drugs 0.000 claims 4
- 108091007928 VEGF receptors Proteins 0.000 claims 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 4
- 108091006028 chimera Proteins 0.000 claims 4
- 229960005386 ipilimumab Drugs 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108010072993 tremelimumab Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000004083 survival Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892601P | 2013-10-18 | 2013-10-18 | |
| US61/892,601 | 2013-10-18 | ||
| US201361901596P | 2013-11-08 | 2013-11-08 | |
| US61/901,596 | 2013-11-08 | ||
| US201461952923P | 2014-03-14 | 2014-03-14 | |
| US61/952,923 | 2014-03-14 | ||
| US201462055734P | 2014-09-26 | 2014-09-26 | |
| US62/055,734 | 2014-09-26 | ||
| PCT/US2014/061071 WO2015058048A1 (en) | 2013-10-18 | 2014-10-17 | Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539096A JP2016539096A (ja) | 2016-12-15 |
| JP2016539096A5 true JP2016539096A5 (fi) | 2017-11-09 |
| JP6607850B2 JP6607850B2 (ja) | 2019-11-20 |
Family
ID=51844874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524116A Active JP6607850B2 (ja) | 2013-10-18 | 2014-10-17 | Ｖｅｇｆアンタゴニスト及び抗ｃｔｌａ−４抗体の組み合わせを含む方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9968674B2 (fi) |
| EP (1) | EP3057990B1 (fi) |
| JP (1) | JP6607850B2 (fi) |
| KR (1) | KR102338453B1 (fi) |
| CN (1) | CN105636986B (fi) |
| AU (1) | AU2014337135B2 (fi) |
| CA (1) | CA2926853C (fi) |
| EA (1) | EA037890B1 (fi) |
| IL (1) | IL244599B (fi) |
| MX (1) | MX2016004736A (fi) |
| WO (1) | WO2015058048A1 (fi) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2004697A2 (en) | 2006-04-07 | 2008-12-24 | The Procter & Gamble Company | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof |
| CN106414474B (zh) | 2014-03-17 | 2021-01-15 | 阿德夫拉姆生物技术股份有限公司 | 用于视锥细胞中增强的基因表达的组合物和方法 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| MY187898A (en) | 2015-03-02 | 2021-10-27 | Adverum Biotechnologies Inc | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| LT3303394T (lt) | 2015-05-29 | 2020-10-12 | Agenus Inc. | Anti-ctla-4 antikūnai ir jų naudojimo būdai |
| AU2016370821A1 (en) | 2015-12-18 | 2018-07-12 | Biogen Ma Inc. | Bispecific antibody platform |
| EP3397276A4 (en) | 2015-12-30 | 2019-12-18 | Kodiak Sciences Inc. | ANTIBODIES AND CONJUGATES THEREOF |
| WO2017165778A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| RS61311B1 (sr) * | 2016-06-16 | 2021-02-26 | Adverum Biotechnologies Inc | Lečenje amd korišćenjem varijante aav2 sa afliberceptom |
| JP7107914B2 (ja) | 2016-07-20 | 2022-07-27 | アイポイント ファーマシューティカルズ， インコーポレイテッド | ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体 |
| MD3551660T2 (ro) | 2016-12-07 | 2024-03-31 | Agenus Inc | Anticorpi anti-CTLA-4 și procedee de utilizare a acestora |
| US11168327B2 (en) | 2017-01-31 | 2021-11-09 | Research Development Foundation | STEAP2 inhibitors for the treatment of liver cancers |
| AU2019214865A1 (en) * | 2018-02-02 | 2020-09-17 | OncoC4, Inc. | Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects |
| CN112135632A (zh) * | 2018-02-02 | 2020-12-25 | 肿瘤免疫股份有限公司 | 选择和设计用于癌症疗法的更安全且更有效的抗ctla-4抗体的方法 |
| US20210040212A1 (en) * | 2018-02-02 | 2021-02-11 | Oncolmmune, Inc. | Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects |
| CN112203679A (zh) * | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES TARGETING HPTP-ß (VE-PTP) AND VEGF |
| KR20230051630A (ko) * | 2018-10-31 | 2023-04-18 | 바이오아트라, 인코퍼레이티드 | 항-ctla4 항체, 항체 단편, 이들의 면역접합체 및 그 용도 |
| CN111378044B (zh) * | 2018-12-28 | 2022-07-15 | 长春金赛药业有限责任公司 | 抗体融合蛋白、制备方法及其应用 |
| MX2021008983A (es) * | 2019-01-30 | 2021-09-08 | Amgen Inc | Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos. |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19802753A1 (de) | 1998-01-26 | 1999-07-29 | Merck Patent Gmbh | Coreaktive Trägermaterialien zur Heterogenisierung von Katalysatoren, Cokatalysatoren und Liganden |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7303746B2 (en) * | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| AU784012B2 (en) | 1999-08-24 | 2006-01-12 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
| IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| MX2007003804A (es) * | 2004-11-04 | 2007-04-23 | Pfizer Prod Inc | Tratamiento combinado de anticuerpo anti-ctla4 e inhibidor de aromatasa para el cancer de mama. |
| WO2007113648A2 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| CA2702637A1 (en) * | 2007-10-22 | 2009-04-30 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| WO2009100140A1 (en) | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
-
2014
- 2014-10-17 KR KR1020167013164A patent/KR102338453B1/ko active IP Right Grant
- 2014-10-17 MX MX2016004736A patent/MX2016004736A/es active IP Right Grant
- 2014-10-17 US US15/026,460 patent/US9968674B2/en active Active
- 2014-10-17 AU AU2014337135A patent/AU2014337135B2/en active Active
- 2014-10-17 JP JP2016524116A patent/JP6607850B2/ja active Active
- 2014-10-17 EA EA201690633A patent/EA037890B1/ru unknown
- 2014-10-17 WO PCT/US2014/061071 patent/WO2015058048A1/en active Application Filing
- 2014-10-17 EP EP14792686.9A patent/EP3057990B1/en active Active
- 2014-10-17 CN CN201480054902.1A patent/CN105636986B/zh active Active
- 2014-10-17 CA CA2926853A patent/CA2926853C/en active Active
-
2016
- 2016-03-15 IL IL24459916A patent/IL244599B/en active IP Right Grant
-
2018
- 2018-04-23 US US15/959,595 patent/US10532096B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539096A5 (fi) | ||
| JP7106594B2 (ja) | Ｐｄ－ｌ１に対するヒト抗体 | |
| US10787521B2 (en) | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof | |
| JP2022126847A (ja) | Ｔｉｇｉｔに対する抗体 | |
| JP2021168699A (ja) | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| JP2019506841A5 (fi) | ||
| JP7162535B2 (ja) | 抗ｇｉｔｒ抗体およびその使用 | |
| US20240190999A1 (en) | Multispecific proteins | |
| JP2018501197A5 (fi) | ||
| JP2016527286A5 (fi) | ||
| JP2021098732A (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｅｇｆｒ、ｃｃｒ４、またはｐｄ−ｌ１に結合するタンパク質 | |
| IL296874A (en) | Antibodies specific for the human poliovirus receptor | |
| JP2023145487A (ja) | 抗ｔｉｍ－３抗体のための投与レジメンおよびその使用 | |
| EP3487298A1 (en) | Multimeric cd137/4-1bb binding molecules and uses thereof | |
| EP3043819A1 (en) | Anti-vstm5 antibodies and the use thereof in therapy and diagnosis | |
| JP2017101068A5 (fi) | ||
| JP2016532693A5 (fi) | ||
| JP2015529641A5 (fi) | ||
| RU2012139829A (ru) | АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8 | |
| JP2023062184A (ja) | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍－関連抗原に結合するタンパク質 | |
| JP2020530770A5 (fi) | ||
| JP2015506961A5 (fi) | ||
| JP2022141840A (ja) | Ｂｔｌａ融合タンパク質アゴニストおよびその使用 | |
| JP2022553129A (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 |